Evaluation of grid pattern photocoagulation for macular edema in central vein occlusion. The Central Vein Occlusion Study Group M report.
Evaluation of grid pattern photocoagulation for macular edema in central vein occlusion. The Central Vein Occlusion Study Group M report.
复制标题
DOI：
10.1016/s0161-6420(95)30849-4
复制
发表时间：
1995-10
期刊：
影响因子：
13.7
通讯作者：
J. Clarkson
中科院分区：
文献类型：
--
作者：
J. Clarkson
目的：评价黄斑栅状光凝在保护或提高中心静脉阻塞(CVO)所致黄斑水肿眼的中心视力中的作用。方法：由国家眼科研究所支持的一项多中心随机对照临床试验。资格是根据临床检查结果和照片阅读中心评估的照片文件确定的。随机分为黄斑网状光凝组(77眼)和不治疗组(78眼)。每4个月对患者进行一次为期3年的跟踪调查，直到研究结束。结果：研究人群包括155名患者的155只眼。在随访期的任何时间点，治疗眼和未治疗眼的视力没有差异。治疗组初始中位数视力为20/160，对照组为20/125。治疗组和对照组的最终中位视力分别为20/200和20/160。然而，治疗明显减少了黄斑水肿的血管造影证据。结论：这项研究的结果不支持对符合中心静脉阻塞研究黄斑水肿组资格标准的人群进行黄斑网格光凝的推荐。
Purpose:To evaluate the efficacy of macular grid photocoagulation in preserving or improving central visual acuity in eyes with macular edema due to central vein occlusion (CVO) and best-corrected visual acuity of 20/50 or poorer.Methods:Patients with angiographically documented macular edema due to CVO were entered into a multicenter randomized controlled clinical trial supported by the National Eye Institute. Eligibility was determined based on both clinical examination findings and photographic documentation evaluated at a photograph reading center. Eyes were assigned randomly to macular grid photocoagulation (77 eyes) or no treatment (78 eyes). Patients were followed every 4 months for 3 years or until the end of the study. The outcome measure was visual acuity.Results:The study population consisted of 155 eyes in 155 patients. There was no difference between treated and untreated eyes in visual acuity at any point during the follow-up period. Initial median visual acuity was 20/160 in treated eyes and 20/ 125 in control eyes. Final median visual acuity was 20/200 in treated eyes and 20/160 in control eyes. However, treatment clearly reduced angiographic evidence of macular edema.Conclusion:The results of this study do not support a recommendation for macular grid photocoagulation for the population meeting the Central Vein Occlusion Study macular edema group eligibility criteria.